Seattle Genetics Inc. (NASDAQ:SGEN) shares were down 1.8% during mid-day trading on Monday . The stock traded as low as $41.77 and last traded at $42.17, with a volume of 287,181 shares. The stock had previously closed at $42.96.

Several research analysts have recently issued reports on SGEN shares. Credit Suisse Group AG reaffirmed a “buy” rating and set a $51.00 price objective on shares of Seattle Genetics in a research report on Friday, April 29th. Vetr cut Seattle Genetics from a “strong-buy” rating to a “hold” rating and set a $36.00 target price for the company. in a research report on Wednesday, April 6th. HC Wainwright reissued a “buy” rating and issued a $65.00 target price on shares of Seattle Genetics in a research report on Monday, June 13th. Zacks Investment Research raised Seattle Genetics from a “sell” rating to a “hold” rating in a research report on Tuesday, April 12th. Finally, Cantor Fitzgerald reissued a “buy” rating and issued a $43.00 target price on shares of Seattle Genetics in a research report on Wednesday, June 8th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and nine have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $46.61.

The stock has a 50-day moving average price of $40.59 and a 200 day moving average price of $36.33. The firm’s market capitalization is $5.93 billion.

Seattle Genetics (NASDAQ:SGEN) last announced its earnings results on Thursday, April 28th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.09) by $0.06. The firm earned $111.15 million during the quarter, compared to analyst estimates of $116.49 million. During the same quarter last year, the firm posted ($0.17) earnings per share. The business’s revenue was up 35.3% on a year-over-year basis. On average, analysts anticipate that Seattle Genetics Inc. will post ($1.10) earnings per share for the current year.

In related news, CEO Clay B. Siegall sold 7,618 shares of Seattle Genetics stock in a transaction dated Wednesday, July 6th. The stock was sold at an average price of $40.56, for a total value of $308,986.08. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Clay B. Siegall sold 22,083 shares of Seattle Genetics stock in a transaction dated Monday, June 6th. The stock was sold at an average price of $43.59, for a total value of $962,597.97. Following the completion of the transaction, the chief executive officer now owns 566,538 shares of the company’s stock, valued at $24,695,391.42. The disclosure for this sale can be found here.

A number of institutional investors have recently bought and sold shares of SGEN. Great West Life Assurance Co. Can increased its position in Seattle Genetics by 17.4% in the fourth quarter. Great West Life Assurance Co. Can now owns 23,618 shares of the company’s stock worth $1,061,000 after buying an additional 3,497 shares during the period. Commerzbank Aktiengesellschaft FI increased its position in Seattle Genetics by 274.9% in the fourth quarter. Commerzbank Aktiengesellschaft FI now owns 25,323 shares of the company’s stock worth $1,136,000 after buying an additional 18,569 shares during the period. Public Employees Retirement Association of Colorado increased its position in Seattle Genetics by 1.4% in the fourth quarter. Public Employees Retirement Association of Colorado now owns 27,234 shares of the company’s stock worth $1,222,000 after buying an additional 367 shares during the period. Trexquant Investment LP increased its position in Seattle Genetics by 37.8% in the fourth quarter. Trexquant Investment LP now owns 29,480 shares of the company’s stock worth $1,323,000 after buying an additional 8,080 shares during the period. Finally, Whalerock Point Partners LLC increased its position in Seattle Genetics by 47.7% in the fourth quarter. Whalerock Point Partners LLC now owns 38,550 shares of the company’s stock worth $1,730,000 after buying an additional 12,450 shares during the period.

Seattle Genetics, Inc is a biotechnology company focused on the development and commercialization of therapies for the treatment of cancer. The Company’s product ADCETRIS, or brentuximab vedotin, is an antibody-drug conjugate (ADC), comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E (MMAE).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.